The schizophrenia market attained a value of USD 8.23 Billion in 2025. The market is further expected to grow in the forecast period of 2026-2035 at a CAGR of 5.80%, to reach USD 14.46 Billion by 2035.
Base Year
Historical Period
Forecast Period
The factors driving the schizophrenia market include the increased occurrence of schizophrenia and improving mental health awareness.
In December 2023, Bristol Myers Squibb acquired Karuna Therapeutics to enhance its neuroscience business segment. This acquisition, coupled with the launches of new drugs like KarXT, shows that there has been rising interest in the development of better and more effective treatments for schizophrenia.
The United States holds a significant market share as it has the highest healthcare expenditure, well-developed healthcare facilities, and a high emphasis on investing in research and development.
Compound Annual Growth Rate
5.8%
Value in USD Billion
2026-2035
*this image is indicative*
Schizophrenia is a psychological disorder that describes a series of abnormalities in behavior, thinking, emotional response, and social interaction. It requires a range of therapeutic interventions, such as antipsychotics and psychosocial treatments, to enhance the standard of living. Time and appropriate management strategies are critical if better results are to be obtained. This has resulted in mergers and acquisitions among key players in the market to satisfy the increasing needs of the population for new therapeutic agents.
Rising Prevalence of Schizophrenia Drive the Market in the Forecast Period
Schizophrenia is one of the ten leading causes of life disability, and it occurs in approximately 1% of the world population. This has led to a higher expectation of better treatments and health care services. Both the pharmaceutical industry and healthcare providers are now focusing their efforts on the development of better ways of managing symptoms as well as enhancing the quality of the lives of patients.
In December 2023, Bristol Myers Squibb (BMS) acquired Karuna Therapeutics for USD 14 billion to strengthen its neuroscience division. The acquisition focuses on the development of KarXT, a novel M1/M4 muscarinic receptor agonist, for the treatment of schizophrenia and Alzheimer’s disease psychosis. The drug is planned to be introduced into the United States market in late 2024 for the treatment of schizophrenia in adults.
In January 2023, Newron Pharmaceuticals S.p.A provided six-month interim data from a clinical trial conducted in Italy concerning the use of evenamide as an add-on treatment option for schizophrenia patients who failed to respond to first-line antipsychotics. The trial involved 100 patients, and all of them noticed improvements in the symptoms of treatment-resistant schizophrenia (TRS) after the six-month trial and a doubling of improved conditions in comparison with the outcome of the six-week trial. This was assessed using the Positive and Negative Syndrome Scale (PANNS) and Clinical Global Impression of Severity (CGI-S), which also revealed positive, statistically significant improvements. The therapy was side-effect-free and was an important sign of a better approach to TRS.
Schizophrenia Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Gender
Market Breakup by Distribution Channel
Market Breakup by Region
The Oral Route is Anticipated to Have the Largest Market Share Based on the Route of Administration
Based on the route of administration, the schizophrenia market is divided into oral, parenteral, and others. The oral route is expected to dominate the market because of its better patient acceptance. They are easier to take than injectable medicines and, hence, promote patient compliance.
Males Lead the Market Share Based on Gender
Based on gender, the schizophrenia market is divided into male and female, with the male segment leading due to a higher prevalence of schizophrenia in males compared to females. This gender difference affects the present market scenario for schizophrenia by promoting the need for therapeutic strategies. The pharmaceutical industry and healthcare sectors are targeting men’s health in research to enhance health solutions with the view of providing better treatments for this specific audience.
Based on regional segmentation, the schizophrenia market is categorized into key regions including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. Among these, the United States holds the largest market share because of factors including a high percentage of healthcare spending, advanced healthcare systems, a high level of investment in research and development, and a comparatively higher incidence of schizophrenia than other parts of the world. The well-developed pharmaceutical industry in the United States concentrates on the creation of new products for schizophrenia treatment. This dominance affects the present market situation in various ways, such as by affecting global treatment protocols, clinical research, and the incorporation of new therapeutic regimes.
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1887 and based in New York, United States, the company provides schizophrenia medications including Abilify Maintena used for maintenance treatment and the Otsuka collaboration products including Rexulti employed to handle several parameters of schizophrenia.
This England-based pharma company, founded in 1999, offers drugs including Seroquel (quetiapine) which is prescribed for schizophrenia and bipolar disorder with the intent to mitigate manifesting symptoms and enhance the patient’s quality of life.
An American company, established in 1876, it is involved in the treatment of schizophrenia through drugs including Zyprexa(olanzapine), aimed at controlling certain aspects of the disease.
It is a Japanese pharmaceutical company founded in 1897. It contributes to schizophrenia treatment with products such as Risperdal, which is applied for stabilizing schizophrenic symptoms and enhancing the functional status of the patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Johnson & Johnson Services, Inc., Pfizer, Inc., Vanda Pharmaceuticals, Allergan, Inc., H. Lundbeck A/S, Alkermes plc, AbbVie Inc., Acadia Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Reviva Pharmaceuticals Holdings, Inc., and Newron Pharmaceuticals Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been in the report.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Gender |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share